19th November, 2008.

Eastland Medical Systems LTD

The Manager
Company Announcement Platform
ASX Limited
20 Bridge Street
Sydney. N.S.W. 2000

By: E-Lodgement of 7 pages.

ASX ANNOUNCEMENT
RESULTS OF GENERAL MEETING

Eastland Medical Systems Ltd held its Annual General Meeting on 19 November 2008 at 2.30 p.m. WST this afternoon. The Resolutions contained in the Notice of Meeting, were dealt with and passed by shareholders and, in accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company wishes to advise the following:

Resolution 1: Ordinary Resolution:
Non-binding advisory vote on the Remuneration Report, "That the Remuneration Report as set out in the Annual Report for the financial year ended 30 June 2008, be adopted."

was passed by a show of hands.

The total number of proxy votes in respect of this Resolution specified that:

(i) The proxy is to vote for the resolution	(number of shares)	(46,796,574)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the resolution	(number of shares)	(2,080,790)
(iii) The proxy is to vote against the resolution	(number of shares)	(722,375)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(2,020,467)

Resolution 2: Ordinary Resolution:
"To re-elect Mr. Peter Jooste QC, retiring by rotation in accordance with clause 3.6 (b) of the Company's Constitution, and being eligible offers himself for re-election."

was passed by a show of hands.

The total number of proxy votes in respect of this Resolution specified that:

(i) The proxy is to vote for the resolution	(number of shares)	(47,527,699)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the resolution	(number of shares)	(1,754,540)
(iii) The proxy is to vote against the resolution	(number of shares)	(435,500)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(1,902,467)

Resolution 3: Ordinary Resolution:
"To re-elect Mr. David Whitelaw, retiring by rotation in accordance with clause 3.6 (b) of the Company's Constitution, and being eligible offers himself for re-election"

was passed by a show of hands.

The total number of proxy votes in respect of this Resolution specified that:

(i) The proxy is to vote for the resolution	(number of shares)	(45,607,699)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the resolution	(number of shares)	(3,706,540)
(iii) The proxy is to vote against the resolution	(number of shares)	(395,500)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(1,910,467)

54 Lindsay Street,
Perth 6000

PO Box 8027
Perth Business Centre
6849

(T) 61 8 9436 9500
(F) 08 9436 9505
www.eastlandmedical.com.au
ACN 090 987 250

Resolution 4: Ordinary Resolution:

"That pursuant to Listing Rule 7.4 of the Listing Rules of ASX Limited, and for all other purposes, shareholders ratify the allotment and issue of 500,000 fully paid ordinary shares issued at $0.15 cents per share, to Calvin Ross."

was passed by a show of hands.

The total number of proxy votes in respect of the Resolution specified that:

(i) The proxy is to vote for the resolution		(49,210,791)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the Resolution	(number of shares)	(1,794,540)
(iii) The proxy is to vote against the resolution	(number of shares)	(606,875)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(8,000)

The Company disregarded any votes cast by Mr Ross of this allotment and by any associates of that person.

Resolution 5: Ordinary Resolution:

"That pursuant to Listing Rule 7.4 of the Listing Rules of ASX Limited, and for all other purposes, shareholders ratify the allotment and issue of 13,347 fully paid ordinary shares issued at $0.30 cents per share, to Alistair Tite."

was passed by a show of hands.

The total number of proxy votes in respect of the Resolution specified that:

(i) The proxy is to vote for the resolution		(49,250,791)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the Resolution	(number of shares)	(1,754,540)
(iii) The proxy is to vote against the resolution	(number of shares)	(606,875)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(8,000)

The Company disregarded any votes cast by Mr Tite of this allotment and by any associates of that person.

Resolution 6: Ordinary Resolution:

"That pursuant to Listing Rule 7.4 of the Listing Rules of ASX Limited, and for all other purposes, shareholders ratify the allotment and issue of 4,662,603 fully paid ordinary shares issued for cash at $0.14 cents per share to sophisticated investors of RM Capital."

was passed by a show of hands.

The total number of proxy votes in respect of the Resolution specified that:

(i) The proxy is to vote for the resolution		(49,250,791)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the Resolution	(number of shares)	(1,754,540)
(iii) The proxy is to vote against the resolution	(number of shares)	(606,875)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(8,000)

The Company disregarded any votes cast by the recipients of this allotment and by any associates of those persons.

Resolution 7: Ordinary Resolution:

"That pursuant to Listing Rule 7.4 of the Listing Rules of ASX Limited, and for all other purposes, shareholders ratify the allotment and issue of 4,662,603 ordinary listed Options exercisable at $0.20 cents per Option expiring 31st May 2011 issued for cash at $0.005 cents per Option to sophisticated investors of R.M. Capital."

was passed by a show of hands.

The total number of proxy votes in respect of the Resolution specified that:

(i) The proxy is to vote for the resolution		(49,250,791)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the Resolution	(number of shares)	(1,754,540)
(iii) The proxy is to vote against the resolution	(number of shares)	(606,875)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(8,000)

The Company disregarded any votes cast by the recipients of this allotment and by any associates of those persons.

Resolution 8: Ordinary Resolution:

"That pursuant to Listing Rule 7.4 of the Listing Rules of ASX Limited, and for all other purposes, shareholders ratify the allotment and issue of 652,764 ordinary listed Options exercisable at $0.20 cents per Option expiring 31st May 2011 issued to R.M. Capital Pty Ltd."

was passed by a show of hands.

The total number of proxy votes in respect of the Resolution specified that:

(i) The proxy is to vote for the resolution		(46,179,906)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the Resolution	(number of shares)	(1,754,540)
(iii) The proxy is to vote against the resolution	(number of shares)	(3,677,760)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(8,000)

The Company disregarded any votes cast on this resolution by RM Capital Pty Ltd and by any associates of those persons.

Resolution 9: Ordinary Resolution:

"That pursuant to Listing Rule 7.4 of the Listing Rules of ASX Limited, and for all other purposes, shareholders ratify the allotment of 218,540 Convertible Notes at $1.00 with a conversion right of eight (8) fully paid ordinary shares for each $1.00 Note and eight (8) free attaching listed options exercisable at $0.20 cents at any time up until 31 May 2011for each 2 x $1.00 Note."

was passed by a show of hands.

The total number of proxy votes in respect of the Resolution specified that:

(i) The proxy is to vote for the resolution		(48,987,041)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the Resolution	(number of shares)	(1,754,540)
(iii) The proxy is to vote against the resolution	(number of shares)	(621,875)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(256,750)

The Company disregarded any votes cast on this resolution by the Note Holders of this allotment and by any associates of those persons.

Resolution 10: Ordinary Resolution:

"That pursuant to Listing Rule 7.4 of the Listing Rules of ASX Limited, and for all other purposes, shareholders ratify the allotment of 180,000 Convertible Notes at $1.00 with a conversion right of eight (8) fully paid ordinary shares for each $1.00 Note and eight (8) free attaching listed options exercisable at $0.20 cents at any time up until 31 May 2011for each 2 x $1.00 Note."

was passed by a show of hands.

The total number of proxy votes in respect of the Resolution specified that:

(i) The proxy is to vote for the resolution		(48,987,041)
(ii) Chairman's proxy with intent not stated – the Chairman voted in favour of the Resolution	(number of shares)	(1,754,540)
(iii) The proxy is to vote against the resolution	(number of shares)	(621,875)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(256,750)

The Company disregarded any votes cast on this resolution by the Note Holders of this allotment and by any associates of those persons.

Resolution 11: Ordinary Resolution:

"That, for the purposes of and in accordance with the ASX Limited Listing Rule 7.2 Exception 9, and for all other purposes, any issue of securities made to participants under the Eastland Medical Systems Ltd Employee Share Option Plan **(Plan**), in accordance with the terms and conditions of which are summarised in the Explanatory Memorandum accompanying the Notice of Annual General Meeting, be approved as an exception to Listing Rule 7.2."

was passed by a show of hands.

The total number of proxy votes in respect of the Resolution specified that:

(i) The proxy is to vote for the resolution		(46,056,699)
(ii) Chairman’s proxy with intent not stated – the Chairman voted in favour of the Resolution	(number of shares)	(1,754,540)
(iii) The proxy is to vote against the resolution	(number of shares)	(3,552,217)
(iv) The proxy is to vote at the Proxy's discretion	(number of shares)	(Nil)
(v) The proxy is to abstain on the resolution	(number of shares)	(256,750)

The Company disregarded any votes cast on this resolution by the Directors, employees or beneficiaries of this allotment and by any associates of those persons

The Board advises that there was no other business lawfully raised or brought forward at the meeting.

Mr. Dermot Patterson, the Company’s Chief Executive Officer provided his address to shareholders at this afternoon’s meeting and we have attached a copy of this address for release to the market.

Yours sincerely,

Trevor Strahan.
Company Secretary.

2008 ANNUAL GENERAL MEETING - 19 NOVEMBER 2008

EASTLAND MEDICAL SYSTEMS Ltd

CHIEF EXECUTIVE OFFICER'S ADDRESS

Good afternoon ladies and gentlemen, I would like to take a few moments to expand on 3 key areas of the company's operations that have been a focus of management during the year and will continue to be.

The first being the continuing restructure of the Group both at domestic and international levels. We completed the merger of Portland Surgical Products into our Sydney based Medical Industries Australia operation during the first half of this year. As a result we expect an ongoing net cost savings of approximately AUD$400,000 per annum. Medical Industries Australia have over the last 12 months continued to streamline their product offering to better address the needs of the Aged Care sector, which is seen as a key growth area. There has also been greater focus placed on securing exclusive national distribution agreements for new products introduced.

Through the acquisition of Phoenix Medical last November, MIA has been able to enhance its sales efforts, by combining equipment service contracts, either as part of a bundle offering or on their own.
These actions by the management of MIA have lead to the operation delivering positive results and an enhancement in their net profit, which we have begun to see and will have a positive effect to the Group.

Sister company Westcoast Surgical and Medical Supplies based here in Perth, has also undertaken similar reviews of their product mix, to ensure that their have right products to meet the demands from the market here in Western Australia. One sector has been a key driver in this regard, that being mining and resource operations located in our far North and all the way down to areas like Raventhorpe in the South.

Management have been extremely proactive in securing opportunities in this new developing sector and today we see Westcoast Surgical being the lead company supplying the needs of this sector. We are confident that the strong inroads now established into the mining operations for their onsite medical equipment needs will be maintained in the future.

Both Companies are to be congratulated on their forward proactive efforts that have initiated these changes and moved both companies into a new direction.

Next, has been our continued intention to strengthen our position within our international associated companies which have a strategic role to play in relation to our ArTiMist™ sublingual anti malaria treatment. During the year we increased our holding in Star Medical (Botswana) Ltd to 87%.
As we move closer to market entry for ArTiMist™ we will be ensuring that Eastland has full control over the entities that form part of this project.

Further, we are engaging with industry and financial institutional and in that regard have several advanced negotiations with both domestic and international companies to partner for the entry of ArTiMist™, particularly in Africa, as part of those companies social responsibility programs. Confidential submissions for significant grants to fund market entry of ArTiMist™, which has the potential to save the lives of thousands of children have been lodged and are presently being reviewed.

We are moving at a pace in collaboration with our lead pharmaceutical scientist Mr. Calvin Ross who is contracted to Eastland, to finalise the arrangements for the Phase III field trial for ArTiMist™. Following our announcement in September that we had now received the completed independent report and results for the two studies that were conducted in Malaysia and South Africa which formed the Phase I trial for the treatment, we are now ready to proceed to Phase III.

As we saw with phase I, there are considerable requirements that need to be addressed with government bodies and third party consultants who both approve and oversee clinical trials which will now involve patients with malaria, and many who will be in a serious condition and due to our patient profiling, will include children under 5 years of age.

There has been ongoing dialogue with a number of African governments and their medical advisory bodies to lay the groundwork for a trial in their countries. It is essential that we follow the set protocols and ethical approvals as set down by the recognised international conventions in this area, to ensure that we achieve the same significant success in Phase III, as we did for Phase I. It is anticipated that this trial will be ready to commence from the 2nd week of January 2009.

Most recently we were delighted to be able to announce that hc Berlin Pharma AG successfully listed on the Frankfurt stock exchange on the 23 October and added significant value to the Group's assets. hc Berlin Pharma AG is our contracted manufacturer for our Pharmaceutical products and is now advancing their manufacturing facility in Potsdam, where the products will be mass produced. Last week hc Berlin Pharma AG concluded their second grant which allowed them to complete contracts on project management and place an order with a supplier in the United Kingdom, for the supply of the first production filler line, with a capacity of 160 million ppm.

Protocols were also agreed for the lodgment of their third grant application for a further €uro32.0 million, with the application being supported by the Brandenburg State's Ministry of Finance.

Shareholders can look forward to substantial progress of the company's projects in the coming months. Following extensive meetings in Germany last week the Group is targeting to launch 4 pharmaceutical products into the market during 2009, which will result in positive revenues for both Eastland and hc Berlin Pharma AG.

Unfortunately, the company is restricted on the release of information of the progress and other activities at hand, until approval is obtained from third party authorities; also we are bound by international protocols surrounding the granting of required licenses. This has had considerable impact on the ability of the company to make announcements during this development phase. We can assure our shareholders that our decision to form our Pharmaceutical Division could not be more positive for the future of the company.

In conclusion, it is our continued intention to steer the company further into the field of new and unique pharmaceutical treatments being developed by the scientific development company ProtoPharma in the United Kingdom. During the coming year we will continue to position the company to ensure that we can undertake to complete our present projects, with product entering the market, also engage in at least two further new projects.

Eastland's divisions are today in a much stronger position and better placed to take advantage of the opportunities being offered by the market. The management and Board remain committed in our goal of helping to make a difference in the world of healthcare, and with our ArTiMist™ project. Eastland will continue its quest for a significant reduction in the level of deaths in children caused by malaria.

Finally, I would like to personally thank all of our staff for their hard work over the past year.

Thank you.

Dermot Patterson
CEO
Eastland Medical Systems Ltd